|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Pindolol#Adverse Reactions]] |
| {{Pindolol}}
| |
| {{CMG}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| Most adverse reactions have been mild. The incidences listed in the following table are derived from 12-week comparative double-blind, parallel design trials in hypertensive patients given Visken® (pindolol) as monotherapy, given various active control drugs as monotherapy, or given placebo. Data for Visken® (pindolol) and the positive controls were pooled from several trials because no striking differences were seen in the individual studies, with 1 exception. When considering all adverse reactions reported, the frequency of edema was noticeably higher in positive control trials [16% Visken® (pindolol) vs. 9% positive control] than in placebo controlled trials [6%Visken® (pindolol) vs. 3% placebo]. The table includes adverse reactions either volunteered or elicited, and at least possibly drug related, which were reported in greater than 2% of Visken® (pindolol) patients and other selected important reactions.
| |
| | |
| {|
| |
| | |
| | [[File:Pin01.png|800px|thumb]]
| |
| | |
| |}
| |
| The following selected (potentially important) adverse reactions were seen in 2% or fewer patients and their relationship to Visken® (pindolol) is uncertain. CENTRAL NERVOUS SYSTEM: anxiety, lethargy; AUTONOMIC NERVOUS SYSTEM: visual disturbances, hyperhidrosis; CARDIOVASCULAR: bradycardia, claudication, cold extremities, heart block, hypotension, syncope, tachycardia, weight gain; GASTROINTESTINAL: diarrhea, vomiting; RESPIRATORY: wheezing; UROGENITAL: impotence, pollakiuria; MISCELLANEOUS: eye discomfort or burning eyes.
| |
| | |
| ====Potential Adverse Effects====
| |
| | |
| In addition, other adverse effects not aforementioned have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects of Visken® (pindolol).
| |
| | |
| <u>'''Central Nervous System'''</u>: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics.
| |
| | |
| <u>'''Cardiovascular'''</u>: Intensification of AV block. (See CONTRAINDICATIONS)
| |
| | |
| <u>'''Allergic'''</u>: Erythematous rash; fever combined with aching and sore throat; laryngospasm; respiratory distress.
| |
| | |
| <u>'''Hematologic'''</u>: Agranulocytosis; thrombocytopenic and nonthrombocytopenic purpura.
| |
| | |
| <u>'''Gastrointestinal'''</u>: Mesenteric arterial thrombosis; ischemic colitis.
| |
| | |
| <u>'''Miscellaneous'''</u>: Reversible alopecia; Peyronie’s disease.
| |
| | |
| The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with Visken® (pindolol) during investigational use and extensive foreign experience amounting to over 4 million patient-years.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VISKEN (PINDOLOL) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07fe9cc3-1ef2-420c-b45d-7f1e894b6ef9 | publisher = | date = | accessdate = }}</ref>
| |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Beta blockers]]
| |
| [[Category:Drugs]]
| |